mTORC2 Is Activated under Hypoxia and Could Support Chronic Myeloid Leukemia Stem Cells
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms24021234 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Cristina Panuzzo und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AIRC.
Abstract (Originalsprache)
Hypoxia is a critical condition that governs survival, self-renewal, quiescence, metabolic shift and refractoriness to leukemic stem cell (LSC) therapy. The present study aims to investigate the hypoxia-driven regulation of the mammalian Target of the Rapamycin-2 (mTORC2) complex to unravel it as a novel potential target in chronic myeloid leukemia (CML) therapeutic strategies. After inducing hypoxia in a CML cell line model, we investigated the activities of mTORC1 and mTORC2. Surprisingly, we detected a significant activation of mTORC2 at the expense of mTORC1, accompanied by the nuclear localization of the main substrate phospho-Akt (Ser473). Moreover, the Gene Ontology analysis of CML patients’ CD34+ cells showed enrichment in the mTORC2 signature, further strengthening our data. The deregulation of mTOR complexes highlights how hypoxia could be crucial in CML development. In conclusion, we propose a mechanism by which CML cells residing under a low-oxygen tension, i.e., in the leukemia quiescent LSCs, singularly regulate the mTORC2 and its downstream effectors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy.
- Department of Neuroscience Rita Levi Montalcini, Neuroscience Institute Cavalieri Ottolenghi, University of Turin, 10043 Turin, Italy.
- Department of Oncology, University of Turin, 10043 Turin, Italy.
ORCID-Profile: Alessandro Maglione, Simone Rocco, Serena Stanga, Chiara Riganti, Joanna Kopecka, Muhammad Shahzad Ali, Barbara Pergolizzi, Enrico Bracco, Daniela Cilloni
Förderung
- AIRC
Zitieren
APA
Panuzzo, C., Pironi, L., Maglione, A., Rocco, S., Stanga, S., Riganti, C., Kopecka, J., Ali, M. S., Pergolizzi, B., Bracco, E., & Cilloni, D. (2023). mTORC2 Is Activated under Hypoxia and Could Support Chronic Myeloid Leukemia Stem Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24021234
Vancouver
Panuzzo C, Pironi L, Maglione A, Rocco S, Stanga S, Riganti C, et al. mTORC2 Is Activated under Hypoxia and Could Support Chronic Myeloid Leukemia Stem Cells. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24021234
BibTeX
@article{Panuzzo2023,
author = {Panuzzo, Cristina and Pironi, Lucrezia and Maglione, Alessandro and Rocco, Simone and Stanga, Serena and Riganti, Chiara and Kopecka, Joanna and Ali, Muhammad Shahzad and Pergolizzi, Barbara and Bracco, Enrico and Cilloni, Daniela},
title = {mTORC2 Is Activated under Hypoxia and Could Support Chronic Myeloid Leukemia Stem Cells},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms24021234}
}
EUVIMED